These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 34499565)

  • 21. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
    Lee Mortensen G; Harrod-Lui K
    Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
    Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
    Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Respiratory Syncytial Virus-Related Infant Community Deaths.
    Mazur NI; Löwensteyn YN; Willemsen JE; Gill CJ; Forman L; Mwananyanda LM; Blau DM; Breiman RF; Madhi SA; Mahtab S; Gurley ES; El Arifeen S; Assefa N; Scott JAG; Onyango D; Tippet Barr BA; Kotloff KL; Sow SO; Mandomando I; Ogbuanu I; Jambai A; Bassat Q; ; Caballero MT; Polack FP; Omer S; Kazi AM; Simões EAF; Satav A; Bont LJ
    Clin Infect Dis; 2021 Sep; 73(Suppl_3):S229-S237. PubMed ID: 34472576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
    Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
    Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy.
    Abu-Raya B; Reicherz F; Lavoie PM
    Clin Rev Allergy Immunol; 2022 Dec; 63(3):371-380. PubMed ID: 35689745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
    Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
    Smith TRF; Schultheis K; Broderick KE
    Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection.
    Ivanov V; Oomens AGP; Papin JF; Staats R; Reuter DN; Yu Z; Piedra PA; Wellliver RC
    Vaccine; 2021 Jul; 39(30):4063-4071. PubMed ID: 34140172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjustable Algorithmic Tool for Assessing the Effectiveness of Maternal Respiratory Syncytial Virus (RSV) Vaccination on Infant Mortality in Developing Countries.
    Cevigney R; Leary C; Gonik B
    Infect Dis Obstet Gynecol; 2021; 2021():5536633. PubMed ID: 34121834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons learned from COVID-19 vaccine acceptance among pregnant and lactating women from two districts in Kenya to inform demand generation efforts for future maternal RSV vaccines.
    Limaye RJ; Singh P; Fesshaye B; Karron RA
    BMC Pregnancy Childbirth; 2024 Mar; 24(1):221. PubMed ID: 38539077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis.
    Riddell CA; Bhat N; Bont LJ; Dupont WD; Feikin DR; Fell DB; Gebretsadik T; Hartert TV; Hutcheon JA; Karron RA; Nair H; Reiner RC; Shi T; Sly PD; Stein RT; Wu P; Zar HJ; Ortiz JR;
    Vaccine; 2018 Dec; 36(52):8100-8109. PubMed ID: 30473186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.
    Srikantiah P; Klugman KP
    BMC Med; 2023 May; 21(1):177. PubMed ID: 37183242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.
    Zhu T; Zhang C; Yu L; Chen J; Qiu H; Lyu W; Huang S
    Virol Sin; 2015 Oct; 30(5):371-8. PubMed ID: 26511990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine.
    Blunck BN; Rezende W; Piedra PA
    Expert Rev Vaccines; 2021 Apr; 20(4):351-364. PubMed ID: 33733995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies.
    Srikantiah P; Vora P; Klugman KP
    Clin Infect Dis; 2021 Sep; 73(Suppl_3):S177-S179. PubMed ID: 34472571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
    van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
    Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination against RSV: is maternal vaccination a good alternative to other approaches?
    Kaaijk P; Luytjes W; Rots NY
    Hum Vaccin Immunother; 2013 Jun; 9(6):1263-7. PubMed ID: 23442726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.